Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

US — Healthcare Sector
Peers: LFCR  BIAF  ATXG  PXMD  VRAX 

Automate Your Wheel Strategy on SHPH

With Tiblio's Option Bot, you can configure your own wheel strategy including SHPH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SHPH
  • Rev/Share 0.0006
  • Book/Share 0.3269
  • PB 12.9998
  • Debt/Equity 0.3361
  • CurrentRatio 2.7828
  • ROIC -2.0994

 

  • MktCap 4548881.0
  • FreeCF/Share -0.8573
  • PFCF -0.528
  • PE -4.0803
  • Debt/Assets 0.2079
  • DivYield 0
  • ROE -12.0291

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
SHPH
Published: June 20, 2025 by: GlobeNewsWire
Sentiment: Neutral

GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that it entered into a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 million, before deducting fees to the placement agent and other offering expenses payable by the Company. The Company intends to use the net proceeds from the offering for potential acquisitions, marketing and other general corporate purposes.

Read More
image for news Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
SHPH
Published: June 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT) announces that the reverse stock split will become effective on June 16, 2025, at 12:01 a.m.

Read More
image for news Shuttle Pharma Announces Reverse Stock Split will Become Effective on June 16, 2025, at 12:01 a.m., Eastern Time
Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
SHPH
Published: March 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), announced today the pricing of an underwritten public offering of 19,166,667 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) at a public offering price of $0.30 per share (the “Offering”). The aggregate gross proceeds to Shuttle Pharma from the Offering are expected to be approximately $5.75 million, before deducting underwriting discounts and commissions and other estimated offering …

Read More
image for news Shuttle Pharma Announces Pricing of $5.75 Million Underwritten Offering
Shuttle Pharma Provides Corporate Update and Reports 2024 Results
SHPH
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

GAITHERSBURG, Md., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2024.

Read More
image for news Shuttle Pharma Provides Corporate Update and Reports 2024 Results

About Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

  • IPO Date 2022-08-31
  • Website https://www.shuttlepharma.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Anatoly Dritschilo
  • Employees 9

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.